Compound EGFR mutations, defined as double or multiple mutations in the EGFR tyrosine
kinase domain, are frequently detected with advances in sequencing technology but its …

Background EGFR mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease.
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …

Mutations in exons 18–21 of the epidermal growth factor receptor gene (EGFR) can confer
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …

Introduction Patients with non-small cell lung cancer (NSCLC) harboring uncommon
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …

Adenocarcinoma is the most common type of non-small cell lung cancer. Some causative
genomic alterations in epidermal growth factor receptor (EGFR), including deletions in exon …

In contrast to other primary epidermal growth factor receptor (EGFR) mutations in lung
adenocarcinomas, insertions in exon 20 of EGFR have been generally associated with …

Introduction Although classic sensitizing mutations of epidermal growth factor receptor
(EGFR) are positive predictive markers for EGFR tyrosine kinase inhibitors (TKIs) in lung …

Purpose To define the prevalence, clinicopathologic characteristics and molecular
associations of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in East …

Purpose It has been reported that EGFR mutations in lung carcinomas make the disease
more responsive to treatment with tyrosine kinase inhibitors. We decided to evaluate the …

Background Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …